TNF and acute myeloid leukemia: These findings suggest that co-inhibition of both TNF/JNK-AP1 and TNF/NF-κB pathways could be a potential therapeutic approach to inhibit leukemic cell growth while protecting HSPC in those AML Fab subtypes which express TNF, such as M3, M4, M5 [76].